HHS: Alzheimer's and Dementia plan (nothing about Vitamin D, etc.) - Oct 2026

Summary of Press Release

Claude AI

HHS released the 2026 Update to the National Plan to Address Alzheimer's Disease and Related Dementias on October 22, 2026. Secretary Kennedy announced it at Broward Health Medical Center in Fort Lauderdale, Florida. HHS describes it as a shift in national strategy toward prevention, earlier detection, and faster development of diagnostics and treatments. The plan's title now formally includes "Related Dementias," which HHS says reflects public input.

Four goals replace the previous six. They are ordered to follow brain health across the lifespan:

Risk reduction across the lifespan: understand risk factors, support healthy aging, and put evidence into practice where it may reduce risk or delay onset.
Discovery and innovation: research, biomarkers, clinical trials, prevention and treatment development, and moving findings into practice.
High-value care: better care from detection and diagnosis through treatment, coordination, and transitions between care settings.
Services and supports for patients and families: caregiver support, long-term and home/community-based services, respite, education, safety, and planning.

Research and putting evidence into practice run through all four goals. The update also highlights infrastructure, biomarkers and early identification, data and measurement, and populations at high risk or disproportionately affected.

New initiatives across 10 agencies:

FDA launched an Alzheimer's Prevention Accelerator to develop new prevention approaches.
ARPA-H announced up to $48.8M in new awards for earlier detection and intervention. Its total Alzheimer's portfolio is now up to $155.3M.
ACL will expand brain-health resources and training for elder justice professionals.
Other HHS efforts include:
- dementia training and screening in health centers
- behavioral health and crisis-response resources for older adults with cognitive decline
- public health approaches to dementia
- studies of diagnostic delays and dementia's economic burden
- an evidence review on prevention
- a test of a lifestyle intervention for beneficiaries with mild cognitive impairment

CMS Administrator Oz focused on easing caregiver burden and expanding access to lifestyle-medicine interventions intended to slow cognitive decline.

Timeline: The update lists priority activities for 2027. HHS says it will measure progress on each goal and report results in the 2027 Update.

Sources:

Nutrition and supplements: almost nothing

The plan never mentions vitamin D, any other vitamin, omega-3/DHA, or dietary supplements. Diet appears only indirectly, through metabolic risk factors and one microbiome project.

Term	In plan?	Where
Vitamin D	No	—
Other vitamins (B12, folate, etc.)	No	—
Omega-3 / DHA	No	—
Dietary supplements	No	—
Mediterranean / MIND diet	No	—
Diet (general)	Once	Gut Microbiome Project, 2027 (p. 21)
Nutrition	Once, in passing	Dietitians listed in VA geriatric training (p. 24)
Natural products	Once	ARPA-H organoid drug-combination screening (p. 21)
Obesity, diabetes, LDL	Yes	Named as vascular/metabolic risk factors (p. 5)
Gut microbiome	Yes	POINTER ancillary study (p. 17); Microbiome Project (p. 21)
Sleep	Yes	POINTER ancillary study (p. 17); ARPA-H UCSF work (landing page)
Air pollution, heavy metals, microplastics	Yes	NIH TOX-AD consortium (p. 14)
Shingles or other infection vaccines	No	Only tau and amyloid vaccines (p. 17)
Hearing or vision loss	No	—
Loneliness / isolation	Landing page only	SAMHSA 2027 awareness day

Named modifiable risk factors

Vascular/metabolic (p. 5): high blood pressure, diabetes, high LDL cholesterol, obesity, smoking, physical inactivity, and excessive alcohol use.
Other contributors (p. 2): stroke, depression, and head trauma, plus genetic, social, economic, educational, and environmental factors.
Caveat: the plan describes the evidence on risk factors and interventions as still evolving.

Risk-reduction evidence the plan highlights

Midlife vascular health: in 30+ years of data on 12,000+ US adults, optimal vascular health was linked to up to 12.6 more dementia-free years (p. 11) [Neurology]
14-country comparison: low education was the more common risk factor in low- and middle-income countries, obesity in high-income ones (p. 11) [PubMed]
ACTIVE trial:
- Speed-of-processing training plus booster sessions cut dementia diagnoses by 25% over 20 years.
- Training without boosters had no effect (p. 17) [PubMed]
U.S. POINTER:
- A two-year multidomain lifestyle program improved global cognition in high-risk older adults.
- Imaging suggests more benefit in people with low hippocampal volume or elevated tau [PubMed]
- Small-vessel brain damage was reduced in participants under 70, but not in those 70+ [PubMed]
- NIH is funding four ancillary studies: neurovascular function, sleep, neuroimaging, and microbiome.
Menopausal hormone therapy timing (pp. 11–12):
- Use after age 70 was linked to faster tau buildup; use before 70 looked neutral or possibly protective.
- Starting more than five years after menopause was linked to more tau pathology [PubMed]
- NIH will fund the first RCT of hormone therapy's effect on brain markers.
Cancer and Alzheimer's: NIH launched a new NIA–NCI collaborative to study their inverse correlation (p. 11).

Evidence baseline and new review (pp. 13–14)

The plan restates the 2017 findings:

AHRQ review: no high-strength evidence for any preventive intervention, moderate-strength evidence for cognitive training, and low-strength evidence for everything else.
NASEM: too little evidence for a public health campaign, but encouraging signs for cognitive training, blood-pressure control in hypertension, and physical activity.

NIH has now contracted NASEM for a new systematic review of research since 2015, plus a consensus study, running 2026–2029.

MAHA ELEVATE (p. 12)

CMS's Innovation Center will test functional and lifestyle-medicine interventions not covered by Original Medicare, including for beneficiaries with cognitive impairment or dementia. The plan gives no details on which interventions qualify, eligibility, sites, or budget.

Prevention-related funding

ARPA-H: $48.8M for three new projects, plus $2.75M at UCSF, for a total portfolio of up to $155.3M. The projects include:
- an 18-month at-home study of adults aged 45–70 with early cognitive concerns, using blood tests to track changes and trial low-risk treatments
- an organoid platform that screens combinations of repurposed drugs and natural products for people with preclinical disease
- a psychedelics RCT in healthy older adults
- AI models trained on donated brain tissue
Department of War CDMRP:
- $4M for about four risk-reduction projects, with a focus on TBI and military service
- $3.2M for about two diagnostics projects
- Award decisions are due by Sept 30, 2027.
FDA Alzheimer's Prevention Accelerator: covers prevention-trial design, biomarkers, model-informed drug development, digital health tools, and outcome measures.
AHRQ: $11M in FY2026 for an All of Us partnership that will run p-tau217 blood tests on about 6,000 participants (p. 20).
CDC:
- 43 BOLD grant recipients
- a cognitive-decline survey module used in 42 states plus DC and Puerto Rico
- a 5th edition of the Healthy Brain Initiative Road Map, planned for 2027

Key numbers (pp. 2–3)

Prevalence: 7.4M Americans with dementia in 2026, projected to reach 13.8M by 2060. A separate NIH-funded figure on p. 27 is 5.7M for adults 51+.
By age: 5.3% at ages 65–74, rising to 34.6% at 85+. Lifetime risk is cited as 50% (p. 12).
Costs: $409B in healthcare and long-term care payments in 2026, and $818B in total societal cost.
Caregivers: 12M+ unpaid caregivers provided 19.6B hours of care in 2025.

Where vitamin D evidence could enter

The main formal channel is the NIH–NASEM review of intervention evidence published since 2015 (2026–2029). MAHA ELEVATE's still-undefined lifestyle-medicine menu is another. The public comment period for this plan closed in August 2026.